CL2021003458A1 - Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. - Google Patents
Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.Info
- Publication number
- CL2021003458A1 CL2021003458A1 CL2021003458A CL2021003458A CL2021003458A1 CL 2021003458 A1 CL2021003458 A1 CL 2021003458A1 CL 2021003458 A CL2021003458 A CL 2021003458A CL 2021003458 A CL2021003458 A CL 2021003458A CL 2021003458 A1 CL2021003458 A1 CL 2021003458A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- diseases
- treatment
- indazole derivatives
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención hace referencia a derivados de 2H-indazol de fórmula (I’), o una sal farmacéuticamente aceptable de este, en los cuales todas las variables son tal como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. Además, la invención proporciona un método para fabricar compuestos de la invención y métodos para su uso terapéutico. La invención también proporciona métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cáncer, una enfermedad cardiovascular, una enfermedad del sistema nervioso central, una enfermedad de la piel, una afección y enfermedad oftálmica, y una enfermedad ósea.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867521P | 2019-06-27 | 2019-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003458A1 true CL2021003458A1 (es) | 2022-08-19 |
Family
ID=71608086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003458A CL2021003458A1 (es) | 2019-06-27 | 2021-12-23 | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230002361A1 (es) |
EP (1) | EP3990432A1 (es) |
JP (1) | JP2022539374A (es) |
KR (1) | KR20220042132A (es) |
CN (1) | CN114585609B (es) |
AR (1) | AR119244A1 (es) |
AU (1) | AU2020304036A1 (es) |
BR (1) | BR112021026369A2 (es) |
CA (1) | CA3145043A1 (es) |
CL (1) | CL2021003458A1 (es) |
CO (1) | CO2022000657A2 (es) |
CR (1) | CR20220036A (es) |
IL (1) | IL289167A (es) |
JO (1) | JOP20210324A1 (es) |
MA (1) | MA56392A (es) |
MX (1) | MX2021015499A (es) |
PE (1) | PE20220517A1 (es) |
TW (1) | TW202116735A (es) |
UY (1) | UY38765A (es) |
WO (1) | WO2020263967A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
WO2022140415A1 (en) * | 2020-12-22 | 2022-06-30 | Biogen Ma Inc. | 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease |
JP2024501282A (ja) * | 2020-12-22 | 2024-01-11 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ[1,2-a]ピリジニル誘導体と疾患の治療におけるその使用 |
WO2023283610A1 (en) * | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
JP2024529501A (ja) | 2022-02-14 | 2024-08-06 | アストラゼネカ・アクチエボラーグ | Irak4阻害剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
AU2007232297B2 (en) * | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
NZ575410A (en) * | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
CN105121415B (zh) * | 2013-03-15 | 2018-10-12 | 生物马林药物股份有限公司 | Hdac抑制剂 |
CN106573932B (zh) * | 2014-08-22 | 2019-07-30 | 默克专利股份公司 | 吲唑类 |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
EA201890307A1 (ru) * | 2015-07-15 | 2018-10-31 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные и азаиндазольные соединения как ингибиторы irak-4 |
CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
CN105559944B (zh) * | 2015-12-14 | 2016-11-09 | 李雷 | 覆膜血管支架 |
US10435396B2 (en) * | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
-
2020
- 2020-06-24 JO JOP/2021/0324A patent/JOP20210324A1/ar unknown
- 2020-06-24 WO PCT/US2020/039346 patent/WO2020263967A1/en active Application Filing
- 2020-06-24 AU AU2020304036A patent/AU2020304036A1/en not_active Abandoned
- 2020-06-24 EP EP20740146.4A patent/EP3990432A1/en active Pending
- 2020-06-24 PE PE2021002236A patent/PE20220517A1/es unknown
- 2020-06-24 CA CA3145043A patent/CA3145043A1/en active Pending
- 2020-06-24 KR KR1020227003147A patent/KR20220042132A/ko unknown
- 2020-06-24 JP JP2021577477A patent/JP2022539374A/ja active Pending
- 2020-06-24 CR CR20220036A patent/CR20220036A/es unknown
- 2020-06-24 AR ARP200101792A patent/AR119244A1/es unknown
- 2020-06-24 MA MA056392A patent/MA56392A/fr unknown
- 2020-06-24 CN CN202080053737.3A patent/CN114585609B/zh active Active
- 2020-06-24 BR BR112021026369A patent/BR112021026369A2/pt not_active Application Discontinuation
- 2020-06-24 MX MX2021015499A patent/MX2021015499A/es unknown
- 2020-06-24 US US17/623,182 patent/US20230002361A1/en active Pending
- 2020-06-24 UY UY0001038765A patent/UY38765A/es unknown
- 2020-06-24 TW TW109121728A patent/TW202116735A/zh unknown
-
2021
- 2021-12-20 IL IL289167A patent/IL289167A/en unknown
- 2021-12-23 CL CL2021003458A patent/CL2021003458A1/es unknown
-
2022
- 2022-01-25 CO CONC2022/0000657A patent/CO2022000657A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA56392A (fr) | 2022-05-04 |
WO2020263967A1 (en) | 2020-12-30 |
AU2020304036A1 (en) | 2022-01-06 |
MX2021015499A (es) | 2022-04-20 |
CN114585609A (zh) | 2022-06-03 |
CO2022000657A2 (es) | 2022-04-29 |
AR119244A1 (es) | 2021-12-01 |
PE20220517A1 (es) | 2022-04-07 |
UY38765A (es) | 2021-01-29 |
JP2022539374A (ja) | 2022-09-08 |
KR20220042132A (ko) | 2022-04-04 |
EP3990432A1 (en) | 2022-05-04 |
WO2020263967A8 (en) | 2021-01-28 |
CR20220036A (es) | 2022-05-04 |
IL289167A (en) | 2022-02-01 |
CA3145043A1 (en) | 2020-12-30 |
BR112021026369A2 (pt) | 2022-05-17 |
TW202116735A (zh) | 2021-05-01 |
US20230002361A1 (en) | 2023-01-05 |
JOP20210324A1 (ar) | 2023-01-30 |
CN114585609B (zh) | 2024-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022000657A2 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
CO2022000659A2 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
DOP2019000273A (es) | Compuestos de heteroarilo bicíclicos 66 fusionados y su uso como inhibidores de LATS | |
ES2652595T3 (es) | Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas | |
CY1117357T1 (el) | Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων | |
ECSP19078393A (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
CO2020006224A2 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
CY1124970T1 (el) | Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
UY39559A (es) | Compuestos y su uso | |
BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
CO2023009313A2 (es) | Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
CO2023001509A2 (es) | Cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
MX2020009355A (es) | Un farmaco para tratar trastornos de una funcion de ogano o tejido y enfermedades acompa?adas por esos trastornos, y el metodo para obtenerlo. | |
CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
AR123017A1 (es) | Cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias | |
PE20231562A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO COMO INHIBIDORES DE IRAK4 Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
AR122609A1 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando fournierella massiliensis | |
UY39600A (es) | Inhibidores del receptor del factor de crecimiento epidérmico | |
MX2023012782A (es) | Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares. | |
EA202091647A1 (ru) | Соединения, композиции и способы лечения заболеваний, связанных с ацидозными или гипоксическими пораженными тканями | |
Chernykh et al. | Mesenchymal cells in the treatment of focal brain injury induced by venous circulation disturbances in rats |